Influences of atorvastatin combined with clopidogrel on hypersensitive C-reactive protein and prognosis of patients with unstable angina pectoris / 中国中西医结合急救杂志

ABSTRACT

Objective To observe clinical efficacy of atorvastatin combined with clopidogrel for treatment of patients with unstable angina and its influences on hypersensitive C-reactive protein (hs-CRP) and prognosis of such patients. Methods Data of four hundred and thirty patients with unstable angina pectoris admitted to Tangshan Worker's Hospital from January 2013 to December 2017 were collected, and according to difference in drug application, they were divided into control group and observation group, with 215 patients in each group. Both groups were treated with routine western therapy; the patients in the control group were subjected to enteric-coated aspirin (the initial dose was 300 mg and the maintenance dose 100 mg/d) atorvastatin therapy (20 mg orally taken, once a day) on the basis of conventional therapy, subcutaneous injection of 4.1 kU low molecular weight heparin calcium every 12 hours once time for 7 days; the patients in the observation group were subjected toatorvastatin therapy (similar dosage used in the control group) and clopidogrel therapy (the initial dose was 30 mg and the maintenance dose was 75 mg/d) on the basis of conventional treatment. After both groups were treated for 6 months, their clinical efficacies were evaluated. The differences of cholesterol (TC), triacylglycerol (TG), hs-CRP were compared before and after treatment between the two groups, and the clinical curative effect, and drug adverse reaction were observed in the two groups. Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group [92.56% (199/215) vs. 73.48% (158/215), P < 0.05, P < 0.05]. After treatment, the levels of TC, TG and hs-CRP in the two groups were lower than those before treatment, and the above indexes in the observation group were significantly lower than those in the control group [TC (mmol/L) 2.28±0.29 vs. 3.81±1.33, TG (mmol/L) 4.35±0.32 vs. 7.77±0.24, hs-CRP (mg/L) 5.41±2.26 vs. 7.15±3.22, all P < 0.05].There was no significant difference in the incidence of adverse reactions between the observation group and the control group [7.91% (17/215) vs. 10.25% (22/215), P > 0.05]. Conclusion Atorvastatin combined with clopidogrel for treatment of unstable angina pectoris can effectively lower the level of hs-CRP,and it has important significance for improving the prognosis of such patients.